Literature DB >> 22974473

Effect of the phosphodiesterase-5 inhibitor zaprinast on ischemia-reperfusion injury in rats.

Anthony J Polcari1, Ahmer V Farooq, Michael E Woods, Matthew S Ripsch, Maria Picken, Thomas M T Turk, Fletcher A White.   

Abstract

PURPOSE: The cardiac and renal protective effects of phosphodiesterase-5 (PDE-5) inhibitors against ischemia-reperfusion injury have recently been demonstrated in animal studies. We evaluated the effect of pretreatment with the PDE-5 inhibitor zaprinast on warm renal ischemia in a rat model.
METHODS: Female Sprague-Dawley rats underwent concomitant right nephrectomy and left renal hilar occlusion for 30 minutes. Twelve animals were equally divided into three groups: Group 1 received no pharmacologic pretreatment, group 2 was pretreated with zaprinast 10 mg/kg, and group 3 was pretreated with zaprinast 20 mg/kg. Zaprinast was dissolved in 25% dimethyl sulfoxide and given as a single intraperitoneal injection 30 minutes before surgery. Serum blood urea nitrogen (BUN) and creatinine levels, histopathology, and TUNEL staining for apoptosis were assessed 24 hours postoperatively.
RESULTS: The mean creatinine level for groups 1, 2, and 3 was 0.73 mg/dL, 0.55 mg/dL, and 0.38 mg/dL, respectively. These values were not statistically different (P=0.099). The mean BUN levels of 35.8 mg/dL for group 1, 27.3 mg/dL for group 2, and 23.3 mg/dL for group 3 were also statistically similar (P=0.278). There were no objective differences in histopathologic evaluation or TUNEL staining between the groups.
CONCLUSION: This study did not demonstrate a beneficial effect of zaprinast pretreatment on renal parameters after warm ischemic injury.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 22974473      PMCID: PMC3608021          DOI: 10.1089/end.2012.0198

Source DB:  PubMed          Journal:  J Endourol        ISSN: 0892-7790            Impact factor:   2.942


  20 in total

Review 1.  Acute renal failure.

Authors:  R Thadhani; M Pascual; J V Bonventre
Journal:  N Engl J Med       Date:  1996-05-30       Impact factor: 91.245

2.  An experimental model for assessment of renal recovery from warm ischemia.

Authors:  P Jablonski; B O Howden; D A Rae; C S Birrell; V C Marshall; J Tange
Journal:  Transplantation       Date:  1983-03       Impact factor: 4.939

3.  Comparison of total, selective, and nonarterial clamping techniques during laparoscopic and robot-assisted partial nephrectomy.

Authors:  George L Martin; Jonathan N Warner; Rafael N Nateras; Paul E Andrews; Mitchell R Humphreys; Erik P Castle
Journal:  J Endourol       Date:  2012-01-04       Impact factor: 2.942

Review 4.  Phosphodiesterase 5 enzyme and its inhibitors: update on pharmacological and therapeutical aspects.

Authors:  S K Kulkarni; C S Patil
Journal:  Methods Find Exp Clin Pharmacol       Date:  2004-12

5.  Characterization and effects of methyl-2- (4-aminophenyl)-1, 2-dihydro-1-oxo-7- (2-pyridinylmethoxy)-4-(3,4, 5-trimethoxyphenyl)-3-isoquinoline carboxylate sulfate (T-1032), a novel potent inhibitor of cGMP-binding cGMP-specific phosphodiesterase (PDE5).

Authors:  J Kotera; K Fujishige; H Michibata; K Yuasa; A Kubo; Y Nakamura; K Omori
Journal:  Biochem Pharmacol       Date:  2000-11-01       Impact factor: 5.858

6.  Zaprinast accelerates recovery from established acute renal failure in the rat.

Authors:  Z Guan; S B Miller; J E Greenwald
Journal:  Kidney Int       Date:  1995-06       Impact factor: 10.612

7.  Nephron sparing surgery for appropriately selected renal cell carcinoma between 4 and 7 cm results in outcome similar to radical nephrectomy.

Authors:  Bradley C Leibovich; Michael L Blute; John C Cheville; Christine M Lohse; Amy L Weaver; Horst Zincke
Journal:  J Urol       Date:  2004-03       Impact factor: 7.450

8.  Zaprinast increases cyclic GMP levels in plasma and in aortic tissue of rats.

Authors:  R L Dundore; D M Clas; L T Wheeler; P G Habeeb; D C Bode; R A Buchholz; P J Silver; E D Pagani
Journal:  Eur J Pharmacol       Date:  1993-11-16       Impact factor: 4.432

9.  Possible impact of nitric oxide on the antihypertensive effect of captopril and zaprinast.

Authors:  Mohamed A Ibrahim; Nobunori Satoh; Shiro Ueda
Journal:  Adv Ther       Date:  2003 May-Jun       Impact factor: 3.845

10.  Effect of zaprinast on nitric oxide levels in serum and aortic tissue.

Authors:  M A Ibrahim; H Asai; S Satoh; N Satoh; S Ueda
Journal:  Methods Find Exp Clin Pharmacol       Date:  2004 Jan-Feb
View more
  2 in total

1.  The renoprotective effects of mannitol and udenafil in renal ischemia-reperfusion injury model.

Authors:  Yusuf Özlülerden; Cihan Toktaş; Hülya Aybek; Vural Küçükatay; Nilay Şen Türk; Ali Ersin Zumrutbas
Journal:  Investig Clin Urol       Date:  2017-06-27

Review 2.  Current Concepts on the Reno-Protective Effects of Phosphodiesterase 5 Inhibitors in Acute Kidney Injury: Systematic Search and Review.

Authors:  Georgios Georgiadis; Ioannis-Erineos Zisis; Anca Oana Docea; Konstantinos Tsarouhas; Irene Fragkiadoulaki; Charalampos Mavridis; Markos Karavitakis; Stavros Stratakis; Kostas Stylianou; Christina Tsitsimpikou; Daniela Calina; Nikolaos Sofikitis; Aristidis Tsatsakis; Charalampos Mamoulakis
Journal:  J Clin Med       Date:  2020-04-29       Impact factor: 4.241

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.